Literature DB >> 22064266

Innocuousness and safety of classical swine fever marker vaccine candidate CP7_E2alf in non-target and target species.

Patricia König1, Sandra Blome, Claudia Gabriel, Ilona Reimann, Martin Beer.   

Abstract

Chimeric pestivirus CP7_E2alf is a promising live marker vaccine candidate against classical swine fever. Prior to a possible application in the field, several safety aspects have to be addressed. Due to the fact that CP7_E2alf is based on a bovine viral diarrhea virus backbone, its behavior in ruminants is of particular interest. In the framework of this study, its innocuousness in non-target species was addressed by inoculation of calves, young goats, lambs, and rabbits. To this means, high titres of CP7_E2alf were applied orally to three animals of each species. Additional animals were left as unvaccinated contact controls. During the study, all animals remained clinically healthy, and neither fever nor leukopenia were observed. Virus could not be isolated from purified white blood cells or from nasal or faecal excretions. Moreover, none of the animals (inoculated or contact control) seroconverted. In the target species, innocuousness, shedding and transmission of vaccine virus was addressed in different animal trials that were carried out primarily for the purpose of efficacy, potency or duration of immunity studies. In all experiments, CP7_E2alf proved to be completely safe for the vaccinees and unvaccinated contact controls. Furthermore, no shedding or transmission was detected in any of the experiments. Even after parental vaccination, vaccine virus genome was barely detectable in blood or organ samples of vaccinated animals. Thus, CP7_E2alf can be regarded as completely safe for both target and non-target species.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22064266     DOI: 10.1016/j.vaccine.2011.10.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Differentiation of classical swine fever virus infection from CP7_E2alf marker vaccination by a multiplex microsphere immunoassay.

Authors:  Hongyan Xia; Rajiv Harimoorthy; Balaje Vijayaraghavan; Sandra Blome; Frederik Widén; Martin Beer; Sándor Belák; Lihong Liu
Journal:  Clin Vaccine Immunol       Date:  2014-11-05

Review 2.  A decade of research into classical swine fever marker vaccine CP7_E2alf (Suvaxyn® CSF Marker): a review of vaccine properties.

Authors:  Sandra Blome; Kerstin Wernike; Ilona Reimann; Patricia König; Claudia Moß; Martin Beer
Journal:  Vet Res       Date:  2017-09-15       Impact factor: 3.683

Review 3.  Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.

Authors:  Qiang Wei; Yunchao Liu; Gaiping Zhang
Journal:  Viruses       Date:  2021-03-10       Impact factor: 5.048

4.  A Triple Gene-Deleted Pseudorabies Virus-Vectored Subunit PCV2b and CSFV Vaccine Protects Pigs against PCV2b Challenge and Induces Serum Neutralizing Antibody Response against CSFV.

Authors:  Selvaraj Pavulraj; Katrin Pannhorst; Rhett W Stout; Daniel B Paulsen; Mariano Carossino; Denise Meyer; Paul Becher; Shafiqul I Chowdhury
Journal:  Vaccines (Basel)       Date:  2022-02-16

Review 5.  Novel vaccine strategies against emerging viruses.

Authors:  Adolfo García-Sastre; Ignacio Mena
Journal:  Curr Opin Virol       Date:  2013-03-07       Impact factor: 7.090

Review 6.  The control of classical swine fever in wild boar.

Authors:  Volker Moennig
Journal:  Front Microbiol       Date:  2015-11-06       Impact factor: 5.640

Review 7.  Classical Swine Fever-An Updated Review.

Authors:  Sandra Blome; Christoph Staubach; Julia Henke; Jolene Carlson; Martin Beer
Journal:  Viruses       Date:  2017-04-21       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.